Mesoamerican Nephropathy (MeN): What We Know so Far

被引:23
|
作者
Sanchez Polo, Vicente [1 ]
Garcia-Trabanino, Ramon [2 ,3 ]
Rodriguez, Guillermo [4 ]
Madero, Magdalena [5 ]
机构
[1] Inst Guatemalteco Seguridad Social, Guatemala City, Guatemala
[2] Ctr Hemodialisis, San Salvador, El Salvador
[3] Fondo Social Emergencia Salud, Tierra Blanca, El Salvador
[4] Hosp Dr RA Calderon Guardia, Serv Nephrol, Caja Costarricense Seguro Social, San Jose, Costa Rica
[5] Inst Nacl Cardiol Ignacio Chavez, Div Nephrol, Juan Badiano 1,Col Secc 16, Mexico City 14080, DF, Mexico
关键词
Mesoamerican nephropathy; MeN; heat stress; CKDu; CKDnt; endemic nephropathy; regional nephropathy; CHRONIC KIDNEY-DISEASE; AGRICULTURAL COMMUNITIES; INTERNATIONAL SOCIETY; UNKNOWN ETIOLOGY; CENTRAL-AMERICA; HEAT-STRESS; DEHYDRATION; RISK; DISPARITIES; MORTALITY;
D O I
10.2147/IJNRD.S270709
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
In 2002, a report from El Salvador described a high incidence of chronic kidney disease (CKD) of unknown cause, mostly in young males from specific coastal areas. Similar situations were observed along the Pacific Ocean coastline of other Central American countries and southern Mexico (Mesoamerica). This new form of CKD has been denominated Mesoamerican endemic nephropathy (MeN). The typical presentation of MeN is a young male from an endemic area with a family history of CKD, low eGFR, high serum creatinine, low level of albuminuria, hypokalemia, hyperuricemia, and urine urate crystals. Kidney biopsy demonstrating tubulointerstitial nephritis remains the gold standard for diagnosis but is available only for a minority. Commonly proposed causes include thermal stress/dehydration and/or exposure to environmental pollutants. However, likely, a third factor, which could be genetic or epigenetic, could contribute to the cause and development of the disease, along with social determinants. Currently, preventive measures focus on minimizing workers exposure to thermal stress/dehydration. There are many research opportunities and priorities should include clinical trials to evaluate the efficacy and safety of the current treatment protocols, along with etiological and genetic studies, and the development of kidney disease data systems. Although there is scant and controversial literature with regard s to the etiology, diagnosis and management of the disease, our aim is to provide the reader a vision of the disease based on our experience.
引用
收藏
页码:261 / 272
页数:12
相关论文
共 50 条
  • [41] Lisfranc Sports Injuries: What Do We Know So Far?
    Maduka, Godsfavour C.
    Maduka, Divinegrace C.
    Yusuf, Naeem
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (11)
  • [42] SOURCE APPORTIONMENT OF OXIDATIVE POTENTIAL What We Know So Far
    Stevanovic, Svetlana
    Jovanovic, Maja, V
    Jovasevic-Stojanovic, Milena, V
    Ristovski, Zoran
    THERMAL SCIENCE, 2023, 27 (3B): : 2347 - 2357
  • [43] What do we know about DNA mechanics so far?
    Aggarwal, Abhishek
    Naskar, Supriyo
    Sahoo, Anil Kumar
    Mogurampelly, Santosh
    Garai, Ashok
    Maiti, Prabal K.
    CURRENT OPINION IN STRUCTURAL BIOLOGY, 2020, 64 : 42 - 50
  • [44] Leishmaniasis in transplant patients: what do we know so far?
    Monge-Maillo, Begona
    Lopez-Velez, Rogelio
    CURRENT OPINION IN INFECTIOUS DISEASES, 2024, 37 (05) : 342 - 348
  • [45] SARS-CoV-2; What We Know so far
    Rajani, Huda Fatima
    Alshaikh, Fatima Ahmed
    Anushiravani, Amir
    ARCHIVES OF IRANIAN MEDICINE, 2020, 23 (07) : 498 - 502
  • [46] Smoking and COVID-19: What we know so far
    Shastri, Madhur D.
    Shukla, Shakti D.
    Chong, Wai Chin
    Kc, Rajendra
    Dua, Kamal
    Patel, Rahul P.
    Peterson, Gregory M.
    O'Toole, Ronan F.
    RESPIRATORY MEDICINE, 2021, 176
  • [47] Organic Matter in the Asteroid Ryugu: What We Know So Far
    Potiszil, Christian
    Yamanaka, Masahiro
    Sakaguchi, Chie
    Ota, Tsutomu
    Kitagawa, Hiroshi
    Kunihiro, Tak
    Tanaka, Ryoji
    Kobayashi, Katsura
    Nakamura, Eizo
    LIFE-BASEL, 2023, 13 (07):
  • [48] Monkeypox: what we know about the 2022 outbreak so far
    Looi, Mun-Keat
    BMJ-BRITISH MEDICAL JOURNAL, 2022, 378
  • [49] Rehabilitation Intensity in Ontario: What Do We Know So Far?
    Elizabeth, Linkewich
    Ryan, Metcalfe
    Ruth, Hall
    Sylvia, Quant
    INTERNATIONAL JOURNAL OF STROKE, 2017, 12 : 59 - 60
  • [50] Omalizumab for successful chemotherapy desensitisation: What we know so far
    Bumbacea, Roxana Silvia
    Ali, Selda
    Corcea, Sabina Loredana
    Spiru, Luiza
    Nitipir, Cornelia
    Strambu, Victor
    Bumbacea, Dragos
    CLINICAL AND TRANSLATIONAL ALLERGY, 2021, 11 (10)